Literature DB >> 16597650

Phenotypic heterogeneity in inherited prion disease (P102L) is associated with differential propagation of protease-resistant wild-type and mutant prion protein.

Jonathan D F Wadsworth1, Susan Joiner, Jacqueline M Linehan, Sharon Cooper, Caroline Powell, Gary Mallinson, Jennifer Buckell, Ian Gowland, Emmanuel A Asante, Herbert Budka, Sebastian Brandner, John Collinge.   

Abstract

Inherited prion diseases are caused by PRNP coding mutations and display marked phenotypic heterogeneity within families segregating the same pathogenic mutation. A proline-to-leucine substitution at prion protein (PrP) residue 102 (P102L), classically associated with the Gerstmann-Sträussler-Scheinker (GSS) phenotype, also shows marked clinical and pathological heterogeneity, including patients with a Creutzfeldt-Jakob disease (CJD) phenotype. To date, this heterogeneity has been attributed to temporal and spatial variance in the propagation of distinct protease-resistant (PrP(Sc)) isoforms of mutant PrP. Here, using a monoclonal antibody that recognizes wild-type PrP, but not PrP 102L, we reveal a spectrum of involvement of wild-type PrP(Sc) in P102L individuals. PrP(Sc) isoforms derived from wild-type and mutant PrP are distinct both from each other and from those seen in sporadic and acquired CJD. Such differential propagation of disease-related isoforms of wild-type PrP and PrP 102L provides a molecular mechanism for generation of the multiple clinicopathological phenotypes seen in inherited prion disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16597650     DOI: 10.1093/brain/awl076

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  44 in total

1.  Proteinase K-resistant material in ARR/VRQ sheep brain affected with classical scrapie is composed mainly of VRQ prion protein.

Authors:  J G Jacobs; A Bossers; H Rezaei; L J M van Keulen; S McCutcheon; T Sklaviadis; I Lantier; P Berthon; F Lantier; F G van Zijderveld; J P M Langeveld
Journal:  J Virol       Date:  2011-09-14       Impact factor: 5.103

2.  Requirements for mutant and wild-type prion protein misfolding in vitro.

Authors:  Geoffrey P Noble; Daniel J Walsh; Michael B Miller; Walker S Jackson; Surachai Supattapone
Journal:  Biochemistry       Date:  2015-01-22       Impact factor: 3.162

3.  Glycosylphosphatidylinositol anchor analogues sequester cholesterol and reduce prion formation.

Authors:  Clive Bate; Mourad Tayebi; Alun Williams
Journal:  J Biol Chem       Date:  2010-04-28       Impact factor: 5.157

4.  Aggregation of prion protein with insertion mutations is proportional to the number of inserts.

Authors:  Shuiliang Yu; Shaoman Yin; Chaoyang Li; Poki Wong; Binggong Chang; Fan Xiao; Shin-Chung Kang; Huimin Yan; Gengfu Xiao; Po Tien; Man-Sun Sy
Journal:  Biochem J       Date:  2007-04-15       Impact factor: 3.857

5.  How does the genetic assassin select its neuronal target?

Authors:  James C Stevens; Elizabeth M C Fisher; Simon Mead
Journal:  Mamm Genome       Date:  2011-03-04       Impact factor: 2.957

Review 6.  The consequences of pathogenic mutations to the human prion protein.

Authors:  Marc W van der Kamp; Valerie Daggett
Journal:  Protein Eng Des Sel       Date:  2009-07-14       Impact factor: 1.650

7.  Absence of spontaneous disease and comparative prion susceptibility of transgenic mice expressing mutant human prion proteins.

Authors:  Emmanuel A Asante; Ian Gowland; Andrew Grimshaw; Jacqueline M Linehan; Michelle Smidak; Richard Houghton; Olufunmilayo Osiguwa; Andrew Tomlinson; Susan Joiner; Sebastian Brandner; Jonathan D F Wadsworth; John Collinge
Journal:  J Gen Virol       Date:  2009-03       Impact factor: 3.891

8.  Transmissible spongiform encephalopathies with P102L mutation of PRNP manifesting different phenotypes: clinical, neuroimaging, and electrophysiological studies in Chinese kindred in Taiwan.

Authors:  Nai-Fang Chi; Yi-Chung Lee; Yi-Chun Lu; Hsiu-Mei Wu; Bing-Wen Soong
Journal:  J Neurol       Date:  2009-08-21       Impact factor: 4.849

9.  Clinicopathological Correlates in a PRNP P102L Mutation Carrier with Rapidly Progressing Parkinsonism-dystonia.

Authors:  Chizoba C Umeh; Piyush Kalakoti; Michael K Greenberg; Silvio Notari; Yvonne Cohen; Pierluigi Gambetti; Adrian L Oblak; Bernardino Ghetti; Zoltan Mari
Journal:  Mov Disord Clin Pract       Date:  2016-02-18

10.  Glimepiride reduces the expression of PrPc, prevents PrPSc formation and protects against prion mediated neurotoxicity in cell lines.

Authors:  Clive Bate; Mourad Tayebi; Luisa Diomede; Mario Salmona; Alun Williams
Journal:  PLoS One       Date:  2009-12-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.